Nucleic acid drugs represent a groundbreaking frontier in biopharmaceutics, offering innovative approaches to treat various diseases at the genetic level. These drugs harness the power of nucleic acids, such as RNA and DNA, to target specific genes associated with illnesses. In the realm of biopharmaceutics, nucleic acid drugs hold immense potential for precision medicine, allowing tailored treatments based on individual genetic profiles.
The development of nucleic acid drugs has opened avenues for tackling genetic disorders, cancers, and infectious diseases with unprecedented precision. Their mechanism involves modulating gene expression, silencing harmful genes, or correcting genetic mutations. Despite initial challenges, advancements in delivery systems and formulations have enhanced the stability and bioavailability of nucleic acid drugs.
Biopharmaceutics researchers are actively exploring the therapeutic possibilities of antisense oligonucleotides, siRNA, and gene-editing technologies. As these nucleic acid drugs progress through clinical trials, they signify a paradigm shift in personalized medicine and hold promise for transforming the landscape of biopharmaceutical interventions.
Title : The impact of metal-decorated polymeric nanodots on proton relaxivity
Paulo Cesar De Morais, Catholic University of Brasilia, Brazil
Title : Hepatotoxic botanicals-shadows of pearls
Consolato M Sergi, Universities of Alberta and Ottawa, Canada
Title : Exploring classical ayurvedic drugs in hypertension
Prashant Bhokardankar, Datta Meghe Ayurved College, India
Title : Principles and standards for managing healthcare transformation towards personalized, preventive, predictive, participative precision medicine ecosystems
Bernd Blobel, University of Regensburg, Germany
Title : Personalized and Precision Medicine (PPM) as a unique healthcare model based on design-inspired biotech- & biopharma-driven applications to secure the human healthcare and biosafety
Sergey Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences & InMedStar, Russian Federation
Title : A unique role and and impact of catalytic antibodies (abzymes) in clinical practice: A novel strategy for predicting and preventing relapse in chronic autoimmune conditions
Sergey Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences & InMedStar, Russian Federation
Title : The promise of nanotechnology in personalized & precision medicine: Drug discovery & development being partnered with nanotechnologies via the revolution at the nanoscale
Sergey Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences & InMedStar, Russian Federation
Title : The promising future of the unique translational tool to manage beta-cell population renewal and regeneration to secure the post-diabetic period
Sergey Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences & InMedStar, Russian Federation
Title : Easily injectable, organic solvent free self assembled hydrogel platform for endoscope mediated gastrointestinal polypectomy
Hitasha Vithalani , IIT Gandhinagar, India